Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
| Autor: | Bjanka Vuksan Ćusa, Alma Mihaljević Peleš, Nela Pivac, Anja Dvojkovic, Zorana Kušević, Marcela Konjevod, Saša Jevtović, Marina Šagud, Lucija Tudor, Matea Nikolac Perkovic, Dubravka Svob Strac, Maja Zivkovic, Gordana Nedic Erjavec |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Serotonin Patients Adolescent 03 medical and health sciences Young Adult 0302 clinical medicine Escitalopram Neurotrophic factors Internal medicine mental disorders medicine Humans Platelet Longitudinal Studies Biological Psychiatry Aged Pharmacology Vortioxetine Plasma BDNF Depressive Disorder Major Platelet serotonin business.industry Depression Brain-Derived Neurotrophic Factor Middle Aged medicine.disease depression escitalopram plasma BDNF platelet serotonin patients vortioxetine 030227 psychiatry Peripheral Endocrinology Mechanism of action Major depressive disorder Female medicine.symptom business medicine.drug |
| Popis: | Escitalopram and vortioxetine are efficacious antidepressants. They directly target serotonin (5-HT) system, but vortioxetine mechanism of action is distinct from the one of selective serotonin reuptake inhibitors (SSRIs). Treatment with SSRIs decrease platelet 5-HT concentration and increase peripheral brain-derived neurotrophic factor (BDNF) levels. Since vortioxetine has a multimodal mechanism of action, it is expected to have a greater effect on circulatory BDNF concentration, compared to conventional antidepressants. This longitudinal study aimed to explore and compare the effects of 4-weeks of treatment with vortioxetine and escitalopram on plasma BDNF and platelet 5-HT concentration in patients with major depressive disorder (MDD). The results revealed that vortioxetine significantly increased plasma BDNF concentration (p = .018) and significantly decreased platelet 5-HT concentration (p < .001). Treatment with escitalopram significantly decreased platelet 5-HT concentration (p < .001), but it did not affect plasma BDNF concentration (p = .379). Response to vortioxetine was not predicted by baseline plasma BDNF or platelet 5-HT concentration, but response to escitalopram was predicted by baseline platelet 5-HT concentration. These effects might be due to vortioxetine unique mechanism of action, but the clinical implications are unclear. It remains to be determined whether this finding extends during long-term vortioxetine treatment, and which, if any, clinical effects emerge from BDNF increase. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|